167 related articles for article (PubMed ID: 16369761)
1. [Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma].
Borchmann P; Behringer K; Josting A; Rueffer JU; Schnell R; Diehl V; Engert A; Kvasnicka HM; Thiele J
Pathologe; 2006 Feb; 27(1):47-52. PubMed ID: 16369761
[TBL] [Abstract][Full Text] [Related]
2. Hodgkin's disease: study of treatment intensities and incidences of second malignancies.
Rodriguez MA; Fuller LM; Zimmerman SO; Allen PK; Brown BW; Munsell MF; Hagemeister FB; McLaughlin P; Velasquez WS; Swan F
Ann Oncol; 1993 Feb; 4(2):125-31. PubMed ID: 8448080
[TBL] [Abstract][Full Text] [Related]
3. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence.
Lipshultz SE; Lipsitz SR; Orav EJ
J Clin Oncol; 2007 Jul; 25(21):3179; author reply 3180. PubMed ID: 17634500
[No Abstract] [Full Text] [Related]
4. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
[TBL] [Abstract][Full Text] [Related]
5. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease.
Beaty O; Hudson MM; Greenwald C; Luo X; Fang L; Wilimas JA; Thompson EI; Kun LE; Pratt CB
J Clin Oncol; 1995 Mar; 13(3):603-9. PubMed ID: 7884422
[TBL] [Abstract][Full Text] [Related]
6. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
[TBL] [Abstract][Full Text] [Related]
7. Second malignancies after Hodgkin's disease: the Munich experience.
Munker R; Grützner S; Hiller E; Aydemir U; Enne W; Dietzfelbinger H; Busch M; Haas R; Emmerich B; Schmidt M; Dühmke E; Hölzel D; Wilmanns W
Ann Hematol; 1999 Dec; 78(12):544-54. PubMed ID: 10647878
[TBL] [Abstract][Full Text] [Related]
8. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
[TBL] [Abstract][Full Text] [Related]
9. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.
Schaapveld M; Aleman BM; van Eggermond AM; Janus CP; Krol AD; van der Maazen RW; Roesink J; Raemaekers JM; de Boer JP; Zijlstra JM; van Imhoff GW; Petersen EJ; Poortmans PM; Beijert M; Lybeert ML; Mulder I; Visser O; Louwman MW; Krul IM; Lugtenburg PJ; van Leeuwen FE
N Engl J Med; 2015 Dec; 373(26):2499-511. PubMed ID: 26699166
[TBL] [Abstract][Full Text] [Related]
10. Incidence of second solid cancer in patients after treatment of Hodgkin's disease.
Glanzmann C; Veraguth A; Lütolf UM
Strahlenther Onkol; 1994 Mar; 170(3):140-6. PubMed ID: 8160093
[TBL] [Abstract][Full Text] [Related]
11. Second primary malignancies after treatment for malignant lymphoma.
Okines A; Thomson CS; Radstone CR; Horsman JM; Hancock BW
Br J Cancer; 2005 Aug; 93(4):418-24. PubMed ID: 16106249
[TBL] [Abstract][Full Text] [Related]
12. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
[TBL] [Abstract][Full Text] [Related]
13. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
Moser EC; Noordijk EM; van Leeuwen FE; Baars JW; Thomas J; Carde P; Meerwaldt JH; van Glabbeke M; Kluin-Nelemans HC
Haematologica; 2006 Nov; 91(11):1481-8. PubMed ID: 17043014
[TBL] [Abstract][Full Text] [Related]
14. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
[TBL] [Abstract][Full Text] [Related]
15. [Second malignancies after the therapy of Hodgkin's disease: the Freiburg collective 1940 to 1991].
Slanina J; Heinemann F; Henne K; Moog G; Frommhold H
Strahlenther Onkol; 1999 Apr; 175(4):154-61. PubMed ID: 10230457
[TBL] [Abstract][Full Text] [Related]
16. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
17. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment.
Swerdlow AJ; Barber JA; Hudson GV; Cunningham D; Gupta RK; Hancock BW; Horwich A; Lister TA; Linch DC
J Clin Oncol; 2000 Feb; 18(3):498-509. PubMed ID: 10653865
[TBL] [Abstract][Full Text] [Related]
18. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
[TBL] [Abstract][Full Text] [Related]
19. Peripheral T-cell non-Hodgkin's lymphoma following treatment of nodular lymphocyte predominance Hodgkin's disease.
Rysenga E; Linden MD; Carey JL; Ross CW; Schnitzer B; Sawdyk M; Maeda K
Arch Pathol Lab Med; 1995 Jan; 119(1):88-91. PubMed ID: 7802562
[TBL] [Abstract][Full Text] [Related]
20. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors.
Meadows AT; Obringer AC; Marrero O; Oberlin O; Robison L; Fossati-Bellani F; Green D; Voûte PA; Morris-Jones P; Greenberg M
Med Pediatr Oncol; 1989; 17(6):477-84. PubMed ID: 2586362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
